Clinical Trials Logo
  1. Home
  2. Locally Advanced Solid Tumor
  3. NCT04975958

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Locally Advanced Solid Tumor Clinical Trial

Official title:
An Open-Label, Multicenter, Phase 1a Study of AN2025 and AN0025 in Double Combination With Atezolizumab and in Triple Combination With Atezolizumab in Patients With Advanced Solid Tumors

Clinical Trial Summary

This is an open-label, multicenter, Phase 1a study to evaluate the safety, tolerability, PK and preliminary efficacy of AN2025 and AN0025 in double or triple combination treatments with Atezolizumab in patients with locally advanced/metastatic tumors.

Clinical Trial Description

This is an open-label, multicenter, Phase 1a study to evaluate the safety, tolerability, PK and preliminary efficacy of AN2025 and AN0025 in double or triple combination treatments with Atezolizumab in patients with locally advanced/metastatic tumors. This study consists of three DLT Observation Periods I, II and III. Observations I and II are double combination treatments, which will be conducted in parallel, whereas Observation III (the triple combination treatment) will be initiated only after a thorough review of the safety data from Observations I and II. In all three Observation Periods, a "6 + 3 design" will be utilized for dose finding with dose escalation and de-escalation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04975958
Study type Interventional
Source Adlai Nortye Biopharma Co., Ltd.
Contact Robert Atkinson, PhD, MSCR
Phone 1-919-741-8894
Email robert.atkinson@adlainortye.com
Status Recruiting
Phase Phase 1
Start date September 7, 2021
Completion date June 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05378425 - A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab Phase 1
Recruiting NCT04260802 - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Phase 1/Phase 2
Not yet recruiting NCT05028478 - A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT04250948 - Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer Phase 2
Recruiting NCT06184035 - A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer Phase 1/Phase 2
Completed NCT04914117 - A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours Phase 1
Recruiting NCT04614740 - The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04770688 - Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib Phase 1/Phase 2
Not yet recruiting NCT06415487 - ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) Phase 1
Not yet recruiting NCT06349408 - IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05732831 - Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors Phase 1/Phase 2
Recruiting NCT06028724 - A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
Active, not recruiting NCT03284502 - HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT01390818 - Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04319757 - ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Phase 1
Recruiting NCT03881488 - Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies Phase 1
Recruiting NCT05275478 - Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors Phase 1/Phase 2